Free Trial

China Pharma Q3 2023 Earnings Report

China Pharma logo
$0.28 -0.01 (-4.24%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

China Pharma EPS Results

Actual EPS
-$0.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

China Pharma Revenue Results

Actual Revenue
$1.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

China Pharma Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

China Pharma Earnings Headlines

China Pharma (NYSE:CPHI) Now Covered by StockNews.com
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
China Pharma Holdings, Inc.
See More China Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like China Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on China Pharma and other key companies, straight to your email.

About China Pharma

China Pharma (NYSE:CPHI) develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

View China Pharma Profile

More Earnings Resources from MarketBeat